{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IB+Assessment",
    "query": {
      "intervention": "IB Assessment"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 391,
    "total_pages": 40,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IB+Assessment&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-11T21:32:52.894Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04140526",
      "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Advanced Solid Tumor",
        "Metastatic Melanoma",
        "Metastatic Head and Neck Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Metastatic Colorectal Cancer",
        "Sarcomas",
        "Metastatic Prostate Cancer",
        "Ovarian Cancer",
        "Small Cell Lung Cancer",
        "Metastatic Breast Cancer",
        "Pancreas Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Cervical Cancer",
        "Adenoid Cystic Carcinoma",
        "Salivary Gland Cancer",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "ONC-392",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoC4, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 733,
      "start_date": "2020-09-16",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-05-23",
      "last_synced_at": "2026-09-11T21:32:52.894Z",
      "location_count": 33,
      "location_summary": "Springdale, Arkansas • Davis, California • Downey, California + 27 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04140526"
    },
    {
      "nct_id": "NCT05564650",
      "title": "Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelodysplastic Syndrome",
        "Recurrent Myelodysplastic Syndrome",
        "Refractory Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Navitoclax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2023-01-12",
      "completion_date": "2026-05-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-09-11T21:32:52.894Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05564650"
    },
    {
      "nct_id": "NCT00900302",
      "title": "OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "Up to 120 Years"
      },
      "enrollment_count": 98,
      "start_date": "2005-04",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2016-02-10",
      "last_synced_at": "2026-09-11T21:32:52.894Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00900302"
    },
    {
      "nct_id": "NCT01418001",
      "title": "Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma",
        "Leiomyosarcoma",
        "Malignant Peripheral Nerve Sheath Tumor",
        "Malignant Fibrous",
        "Histiocytoma/Undifferentiated Pleomorphic Sarcoma"
      ],
      "interventions": [
        {
          "name": "Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2011-08",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2018-01-11",
      "last_synced_at": "2026-09-11T21:32:52.894Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Evanston, Illinois • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01418001"
    },
    {
      "nct_id": "NCT01415739",
      "title": "Study of Proteins in Tumor Samples From Patients With Non-Small Cell Lung Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2011-10",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2019-01-24",
      "last_synced_at": "2026-09-11T21:32:52.894Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01415739"
    },
    {
      "nct_id": "NCT03866239",
      "title": "A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cibisatamab",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2019-05-07",
      "completion_date": "2024-03-13",
      "has_results": false,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-09-11T21:32:52.894Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Santa Monica, California • Stanford, California + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03866239"
    },
    {
      "nct_id": "NCT04292119",
      "title": "Lorlatinib Combinations in Lung Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer",
        "Anaplastic Lymphoma Kinase Gene Translocation",
        "ROS1 Rearrangement",
        "Relapsed Cancer",
        "MET Amplification",
        "Resistant Cancer",
        "NSCLC"
      ],
      "interventions": [
        {
          "name": "Lorlatinib",
          "type": "DRUG"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "TNO155",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2020-05-01",
      "completion_date": "2023-03-01",
      "has_results": false,
      "last_update_posted_date": "2021-03-10",
      "last_synced_at": "2026-09-11T21:32:52.894Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04292119"
    },
    {
      "nct_id": "NCT05596045",
      "title": "Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS CoV 2 Infection"
      ],
      "interventions": [
        {
          "name": "ASC10",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascletis Pharmaceuticals Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-11-28",
      "completion_date": "2023-10-09",
      "has_results": false,
      "last_update_posted_date": "2024-11-01",
      "last_synced_at": "2026-09-11T21:32:52.894Z",
      "location_count": 2,
      "location_summary": "Anniston, Alabama • Hialeah, Florida",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05596045"
    },
    {
      "nct_id": "NCT06672705",
      "title": "Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder",
        "EBV-Related Post-Transplant Lymphoproliferative Disorder",
        "Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder",
        "Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder",
        "Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder",
        "Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Epcoritamab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Timothy Voorhees",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2025-06-16",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-19",
      "last_synced_at": "2026-09-11T21:32:52.894Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Columbus, Ohio",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06672705"
    },
    {
      "nct_id": "NCT02129101",
      "title": "Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myelomonocytic Leukemia",
        "de Novo Myelodysplastic Syndrome",
        "Essential Thrombocythemia",
        "Myelodysplastic Syndrome",
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Polycythemia Vera",
        "Previously Treated Myelodysplastic Syndrome",
        "Primary Myelofibrosis",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Sonidegib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2014-05",
      "completion_date": "2019-10-25",
      "has_results": false,
      "last_update_posted_date": "2019-10-30",
      "last_synced_at": "2026-09-11T21:32:52.894Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02129101"
    }
  ]
}